Clearmind Medicine (US:CMND) Globenewswire·2025-12-24 14:15Core Insights - Clearmind Medicine Inc. has made significant progress in 2025, particularly in advancing its lead candidate, CMND-100, for the treatment of Alcohol Use Disorder (AUD) [1][2] Clinical Trial Progress - Clearmind advanced its multinational Phase I/IIa clinical trial for CMND-100, with site activations at prestigious institutions such as Yale School of Medicine and Johns Hopkins University [3] - The company successfully initiated first-in-human dosing, completed treatment and enrollment for the first cohort, and reported positive top-line safety and tolerability results with no serious adverse events [3] - Enrollment and dosing for the second cohort were completed, accelerating the path toward further data readouts [3] Independent Safety Endorsement - Clearmind received unanimous approval from the Data and Safety Monitoring Board (DSMB) to continue the Phase I/IIa clinical trial following an interim review, reinforcing CMND-100's favorable safety profile [4] Global Footprint Expansion - The company strengthened its intellectual property portfolio with multiple international patent filings and publications targeting various indications, including weight loss, obesity, and mental health disorders [5] Leadership Commentary - The CEO of Clearmind highlighted 2025 as a pivotal year for the company, emphasizing its transition into a clinical-stage entity and commitment to delivering transformative treatments for addictions and mental health challenges [6] Intellectual Property Portfolio - Clearmind's intellectual portfolio consists of nineteen patent families, including 31 granted patents, with plans to seek additional patents as warranted [8]